CA
NZ
UK
AU
IND
US
…
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Net income | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Selling general administrative | 38.59M | 23.82M | 14.30M | 5.23M | 2.42M |
| Selling and marketing expenses | - | - | 14.28M | - | - |
| Gross profit | -0.06M | -0.04M | - | - | - |
| Reconciled depreciation | 0.06M | 0.04M | 0.00M | - | - |
| Ebit | -154.65M | -177.81M | -84.82M | -31.48M | -18.73M |
| Ebitda | -154.59M | -177.77M | -71.90M | -31.48M | -18.72M |
| Depreciation and amortization | 0.06M | 0.04M | 0.17M | - | 0.00M |
| Operating income | -170.60M | -192.40M | -84.66M | -31.48M | -18.73M |
| Other operating expenses | 170.60M | 192.40M | 84.66M | 31.48M | 18.73M |
| Interest expense | - | - | - | - | 0.03M |
| Interest income | 15.95M | 14.59M | 10.37M | 1.68M | - |
| Net interest income | 15.95M | 14.59M | 10.37M | 1.68M | -0.03M |
| Income tax expense | - | -177.81M | -0.17M | - | 0.03M |
| Total revenue | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Total operating expenses | 170.60M | 192.40M | 84.66M | 31.48M | 18.73M |
| Cost of revenue | 0.06M | 0.04M | - | - | - |
| Total other income expense net | 15.95M | 14.59M | 12.76M | 0.00M | -0.66M |
| Net income from continuing ops | -154.65M | -177.81M | -56.58M | -29.80M | -19.41M |
| Net income applicable to common shares | - | - | - | -29.80M | -19.41M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 661.81M | 205.90M | 251.64M | 114.44M | 11.12M |
| Other current assets | 4.75M | 7.16M | 12.54M | 2.70M | 0.51M |
| Total liab | 15.11M | 14.65M | 10.48M | 166.71M | 34.05M |
| Total stockholder equity | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M |
| Deferred long term liab | - | - | - | 1.63M | 0.00M |
| Other current liab | 13.10M | 14.17M | 9.88M | 6.16M | 4.29M |
| Common stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Capital stock | 0.01M | 0.01M | 0.00M | 0.00M | 0.00M |
| Retained earnings | -457.17M | -302.52M | -124.71M | -52.81M | -23.01M |
| Other assets | - | - | 0.00M | 1.63M | 0.00M |
| Cash | 172.92M | 114.09M | 49.30M | 87.70M | 10.61M |
| Total current liabilities | 15.11M | 14.65M | 10.48M | 8.07M | 5.05M |
| Net debt | -172.92M | -114.09M | -49.30M | -87.70M | -10.61M |
| Other stockholder equity | 1103.85M | 493.77M | 365.86M | 0.54M | -28.91M |
| Total current assets | 661.39M | 205.35M | 249.10M | 110.11M | 11.12M |
| Long term investments | - | 0.00M | 2.48M | - | - |
| Net tangible assets | - | - | - | -52.27M | -22.93M |
| Short term investments | 483.71M | 84.10M | 187.26M | 22.41M | - |
| Accounts payable | 2.02M | 0.48M | 0.60M | 1.91M | 0.76M |
| Accumulated other comprehensive income | - | - | -251.64M | - | - |
| Non currrent assets other | 0.38M | 0.50M | 0.05M | - | - |
| Non current assets total | 0.42M | 0.55M | 2.53M | 4.33M | 0.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -389.74M | 114.96M | -102.38M | -21.76M | -21.76M |
| Change to liabilities | - | - | - | 3.01M | 4.47M |
| Total cashflows from investing activities | -389.75M | 114.96M | -160.47M | -21.76M | -21.76M |
| Total cash from financing activities | 591.00M | 116.14M | 203.25M | 128.02M | 23.81M |
| Change to operating activities | - | - | - | -2.24M | -0.39M |
| Net income | -154.65M | -177.81M | -71.90M | -29.80M | -19.41M |
| Change in cash | 58.83M | 64.79M | -38.40M | 77.04M | 9.25M |
| Begin period cash flow | 114.09M | 49.30M | 87.70M | 10.66M | 1.41M |
| End period cash flow | 172.92M | 114.09M | 49.30M | 87.70M | 10.66M |
| Total cash from operating activities | -142.42M | -166.31M | -81.17M | -29.22M | -14.56M |
| Issuance of capital stock | 578.36M | 116.06M | 202.99M | 129.65M | 23.81M |
| Depreciation | 0.06M | 0.04M | 0.00M | - | - |
| Change to account receivables | -0.17M | 0.42M | -0.35M | - | - |
| Sale purchase of stock | 0.24M | 0.22M | 0.06M | - | - |
| Other cashflows from financing activities | 591.00M | 0.08M | 0.26M | 128.02M | -1.63M |
| Change to netincome | - | - | - | -0.19M | 0.76M |
| Capital expenditures | 0.01M | 0.10M | 0.00M | 0.00M | 0.00M |
| Change in working capital | 2.73M | 9.52M | -7.47M | 0.77M | 4.08M |
| Stock based compensation | 19.32M | 11.34M | 5.06M | 0.46M | 0.08M |
| Other non cash items | -9.88M | -9.40M | -6.87M | -0.65M | 0.68M |
| Free cash flow | -142.43M | -166.41M | -81.17M | -29.22M | -14.56M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|
| MLYS Mineralys Therapeutics, Inc. Common Stock |
0.25 1.18% |
21.38 | - | - | - | 4.65 | -7.41 |
| NVO Novo Nordisk A/S |
-0.38 0.98% |
38.29 | 41.58 | 31.15 | 2.13 | 32.99 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
8.66 1.66% |
529.69 | 30.22 | 24.27 | 10.36 | 6.50 | 24.66 |
| REGN Regeneron Pharmaceuticals Inc |
-2.83 0.35% |
813.27 | 29.07 | 20.12 | 7.57 | 3.82 | 19.42 |
| ARGNF argenx SE |
- -% |
790.15 | 45.77 | 31.25 | 13.84 | 7.12 | 36.06 |
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
150 N. Radnor Chester Road, Radnor, PA, United States, 19087
888 378 6240
76
| Name | Title | Year Born |
|---|---|---|
| Mr. Jon Congleton | CEO & Director | 1963 |
| Mr. Adam Scott Levy | CFO & Secretary | 1978 |
| Dr. David M. Rodman M.D. | Chief Medical Officer | 1955 |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder & Executive Chairman | 1977 |
| Ms. Cindy Berejikian | Executive Vice President of Operations | NA |
| Ms. Sarah Foster | Vice President of Human Resources | NA |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC | NA |
| Ms. Danielle Bradbury | Senior Vice President of Quality Assurance | NA |
| Mr. Jeffrey N. Fellows | Senior Vice President of Regulatory Affairs | NA |
| Ms. Jessica Ibbitson | Senior Vice President of Clinical Operations | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.02%
Communication Services
-0.63%
Consumer Cyclical
-0.11%
Consumer Defensive
-0.45%
Energy
+0.39%
Financial Services
-0.10%
Financials
-0.81%
Healthcare
+1.03%
Industrials
+0.32%
Real Estate
-0.31%
Technology
+0.59%
Utilities
-0.18%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...